Literature DB >> 1687647

Productive infection of T-helper lymphocytes with feline immunodeficiency virus is accompanied by reduced expression of CD4.

B J Willett1, M J Hosie, T H Dunsford, J C Neil, O Jarrett.   

Abstract

An antigen-specific feline T-lymphocyte cell line (Q201) was generated and infected in vitro with the feline immunodeficiency virus (FIV). Syncytium formation and the release of the viral core protein p24 into culture fluid were accompanied by a reduction in expression of the CD4 surface antigen. The reduction in CD4 expression was transient, the resulting persistently infected population of cells expressing levels of CD4 comparable to those observed prior to infection. Persistently infected cells gradually lost expression of major histocompatibility antigen (MHC) class II while maintaining pre-infection levels of expression of CD4, MHC class I, CD18 or CD29.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687647     DOI: 10.1097/00002030-199112000-00009

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  31 in total

1.  Blocking of feline immunodeficiency virus infection by a monoclonal antibody to CD9 is via inhibition of virus release rather than interference with receptor binding.

Authors:  A de Parseval; D L Lerner; P Borrow; B J Willett; J H Elder
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Feline atopic dermatitis. A model for Langerhans cell participation in disease pathogenesis.

Authors:  P J Roosje; D Whitaker-Menezes; M H Goldschmidt; P F Moore; T Willemse; G F Murphy
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

3.  Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Authors:  Margaret J Hosie; Dieter Klein; James M Binley; Thomas H Dunsford; Oswald Jarrett; James C Neil; Elzbieta Knapp; Simone Giannecchini; Donatella Matteucci; Mauro Bendinelli; James A Hoxie; Brian J Willett
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

4.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Authors:  Mauro Pistello; Donatella Matteucci; Francesca Bonci; Patrizia Isola; Paola Mazzetti; Lucia Zaccaro; Antonio Merico; Daniela Del Mauro; Norman Flynn; Mauro Bendinelli
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 5.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

6.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

7.  Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Authors:  Aymeric de Parseval; Udayan Chatterji; Peiqing Sun; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

8.  Localization of the viral antigen of feline immunodeficiency virus in the lymph nodes of cats at the early stage of infection.

Authors:  T Toyosaki; T Miyazawa; T Furuya; K Tomonaga; Y S Shin; M Okita; Y Kawaguchi; C Kai; S Mori; T Mikami
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 9.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

10.  In vivo CXCR4 expression, lymphoid cell phenotype, and feline immunodeficiency virus infection.

Authors:  Sean P Troth; Alan D Dean; Edward A Hoover
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.